{"id":"https://openalex.org/W2011503104","doi":"https://doi.org/10.1097/01.ftd.0000249944.42859.bf","title":"Pharmacokinetic Variability of Aripiprazole and the Active Metabolite Dehydroaripiprazole in Psychiatric Patients","display_name":"Pharmacokinetic Variability of Aripiprazole and the Active Metabolite Dehydroaripiprazole in Psychiatric Patients","publication_year":2006,"publication_date":"2006-12-01","ids":{"openalex":"https://openalex.org/W2011503104","doi":"https://doi.org/10.1097/01.ftd.0000249944.42859.bf","mag":"2011503104","pmid":"https://pubmed.ncbi.nlm.nih.gov/17164689"},"language":"en","primary_location":{"id":"doi:10.1097/01.ftd.0000249944.42859.bf","doi":"https://doi.org/10.1097/01.ftd.0000249944.42859.bf","is_oa":false,"landing_page_url":"https://doi.org/10.1097/01.ftd.0000249944.42859.bf","pdf_url":null,"source":{"id":"https://openalex.org/S179268941","display_name":"Therapeutic Drug Monitoring","issn_l":"0163-4356","issn":["0163-4356","1536-3694"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Therapeutic Drug Monitoring","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5043781386","display_name":"Espen Molden","orcid":"https://orcid.org/0000-0001-6190-2751","observed_orcids":["https://orcid.org/0000-0001-6190-2751"]},"institutions":[{"id":"https://openalex.org/I4210117451","display_name":"Diakonhjemmet Hospital","ror":"https://ror.org/02jvh3a15","country_code":"NO","type":"healthcare","lineage":["https://openalex.org/I4210117451"]}],"countries":["NO"],"is_corresponding":false,"raw_author_name":"Espen Molden","raw_affiliation_strings":["Department of Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway. emolden@farmasi.uio.no","the Department of Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway. emolden@farmasi.uio.no","institution_ids":["https://openalex.org/I4210117451"]},{"raw_affiliation_string":"the Department of Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway","institution_ids":["https://openalex.org/I4210117451"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062069610","display_name":"Hilde A. Lunde","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117451","display_name":"Diakonhjemmet Hospital","ror":"https://ror.org/02jvh3a15","country_code":"NO","type":"healthcare","lineage":["https://openalex.org/I4210117451"]}],"countries":["NO"],"is_corresponding":false,"raw_author_name":"Hilde Lunde","raw_affiliation_strings":["the Department of Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"the Department of Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway","institution_ids":["https://openalex.org/I4210117451"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039798020","display_name":"Niclas Lunder","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117451","display_name":"Diakonhjemmet Hospital","ror":"https://ror.org/02jvh3a15","country_code":"NO","type":"healthcare","lineage":["https://openalex.org/I4210117451"]}],"countries":["NO"],"is_corresponding":false,"raw_author_name":"Niclas Lunder","raw_affiliation_strings":["the Department of Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"the Department of Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway","institution_ids":["https://openalex.org/I4210117451"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5111711249","display_name":"Helge Refsum","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117451","display_name":"Diakonhjemmet Hospital","ror":"https://ror.org/02jvh3a15","country_code":"NO","type":"healthcare","lineage":["https://openalex.org/I4210117451"]}],"countries":["NO"],"is_corresponding":false,"raw_author_name":"Helge Refsum","raw_affiliation_strings":["the Department of Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"the Department of Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway","institution_ids":["https://openalex.org/I4210117451"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210117451"],"apc_list":null,"apc_paid":null,"fwci":3.4252,"has_fulltext":false,"cited_by_count":83,"citation_normalized_percentile":{"value":0.92248062,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":98},"biblio":{"volume":"28","issue":"6","first_page":"744","last_page":"749"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9726999998092651,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9726999998092651,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.017799999564886093,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10800","display_name":"Forensic Toxicology and Drug Analysis","score":0.0032999999821186066,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/aripiprazole","display_name":"aripiprazole","score":0.9100000262260437},{"id":"https://openalex.org/keywords/dehydroaripiprazole","display_name":"dehydroaripiprazole","score":1.0},{"id":"https://openalex.org/keywords/pharmacokinetic-variability","display_name":"pharmacokinetic variability","score":0.9940000176429749},{"id":"https://openalex.org/keywords/atypical-antipsychotics","display_name":"atypical antipsychotics","score":0.8820000290870667},{"id":"https://openalex.org/keywords/cyp2d6-inhibitors","display_name":"CYP2D6 inhibitors","score":0.8820000290870667},{"id":"https://openalex.org/keywords/paroxetine","display_name":"paroxetine","score":0.8029999732971191},{"id":"https://openalex.org/keywords/fluoxetine","display_name":"fluoxetine","score":0.996999979019165},{"id":"https://openalex.org/keywords/cyp3a4","display_name":"CYP3A4","score":0.796999990940094},{"id":"https://openalex.org/keywords/dose-concentration-relationship","display_name":"dose-concentration relationship","score":0.8510000109672546},{"id":"https://openalex.org/keywords/drug-monitoring","display_name":"drug monitoring","score":0.5230000019073486},{"id":"https://openalex.org/keywords/psychiatric-patients","display_name":"psychiatric patients","score":0.7960000038146973},{"id":"https://openalex.org/keywords/sex-differences","display_name":"sex differences","score":0.5189999938011169},{"id":"https://openalex.org/keywords/drug-metabolism","display_name":"drug metabolism","score":0.41499999165534973},{"id":"https://openalex.org/keywords/c-d-ratio","display_name":"C/D ratio","score":0.4359999895095825},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.503000020980835},{"id":"https://openalex.org/keywords/dopamine-d2-receptor","display_name":"dopamine D2 receptor","score":0.44999998807907104}],"concepts":[{"id":"https://openalex.org/C2780211496","wikidata":"https://www.wikidata.org/wiki/Q411188","display_name":"Aripiprazole","level":3,"score":0.9261484146118164},{"id":"https://openalex.org/C33664856","wikidata":"https://www.wikidata.org/wiki/Q3271142","display_name":"CYP2D6","level":4,"score":0.7259054183959961},{"id":"https://openalex.org/C58732023","wikidata":"https://www.wikidata.org/wiki/Q770260","display_name":"Partial agonist","level":4,"score":0.7026216983795166},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.662455141544342},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6379319429397583},{"id":"https://openalex.org/C2777477808","wikidata":"https://www.wikidata.org/wiki/Q407595","display_name":"Metabolite","level":2,"score":0.5989029407501221},{"id":"https://openalex.org/C149151106","wikidata":"https://www.wikidata.org/wiki/Q4677569","display_name":"Active metabolite","level":3,"score":0.5404589772224426},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4756345748901367},{"id":"https://openalex.org/C109650736","wikidata":"https://www.wikidata.org/wiki/Q424440","display_name":"CYP3A4","level":4,"score":0.4257488548755646},{"id":"https://openalex.org/C2776134451","wikidata":"https://www.wikidata.org/wiki/Q422244","display_name":"Fluoxetine","level":4,"score":0.41101691126823425},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3682088851928711},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3226035237312317},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.28977054357528687},{"id":"https://openalex.org/C526171541","wikidata":"https://www.wikidata.org/wiki/Q407693","display_name":"Cytochrome P450","level":3,"score":0.2275196611881256},{"id":"https://openalex.org/C62231903","wikidata":"https://www.wikidata.org/wiki/Q1057","display_name":"Metabolism","level":2,"score":0.1284005343914032},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.11703294515609741},{"id":"https://openalex.org/C2775864247","wikidata":"https://www.wikidata.org/wiki/Q167934","display_name":"Serotonin","level":3,"score":0.10983479022979736},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.09731754660606384},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.07950848340988159}],"mesh":[{"descriptor_ui":"D000068180","descriptor_name":"Aripiprazole","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005473","descriptor_name":"Fluoxetine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D016903","descriptor_name":"Drug Monitoring","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017374","descriptor_name":"Paroxetine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D065690","descriptor_name":"Cytochrome P-450 CYP2D6 Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1097/01.ftd.0000249944.42859.bf","doi":"https://doi.org/10.1097/01.ftd.0000249944.42859.bf","is_oa":false,"landing_page_url":"https://doi.org/10.1097/01.ftd.0000249944.42859.bf","pdf_url":null,"source":{"id":"https://openalex.org/S179268941","display_name":"Therapeutic Drug Monitoring","issn_l":"0163-4356","issn":["0163-4356","1536-3694"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Therapeutic Drug Monitoring","raw_type":"journal-article"},{"id":"pmid:17164689","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17164689","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Therapeutic drug monitoring","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9922999739646912,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":23,"referenced_works":["https://openalex.org/W1513060850","https://openalex.org/W1528478735","https://openalex.org/W1963984456","https://openalex.org/W1968825227","https://openalex.org/W1970985273","https://openalex.org/W1984962032","https://openalex.org/W1994469037","https://openalex.org/W1994733841","https://openalex.org/W2013970121","https://openalex.org/W2016382954","https://openalex.org/W2026248539","https://openalex.org/W2032164227","https://openalex.org/W2045058338","https://openalex.org/W2067345113","https://openalex.org/W2126772533","https://openalex.org/W2157049173","https://openalex.org/W2160406851","https://openalex.org/W2162820060","https://openalex.org/W2166770851","https://openalex.org/W2333441088","https://openalex.org/W3023832413","https://openalex.org/W4247120520","https://openalex.org/W6631714122"],"related_works":["https://openalex.org/W2255175632","https://openalex.org/W2138236173","https://openalex.org/W4402201797","https://openalex.org/W2908205139","https://openalex.org/W2073419931","https://openalex.org/W1981455112","https://openalex.org/W2090674884","https://openalex.org/W4366132250","https://openalex.org/W2046193077","https://openalex.org/W1988824856"],"abstract_inverted_index":{"Aripiprazole":[0],"is":[1,246,270,282],"a":[2,8,212],"new":[3],"atypical":[4],"antipsychotic":[5],"drug":[6,49,66],"with":[7,56,204],"partial":[9],"agonist":[10],"activity":[11],"at":[12,116],"dopamine":[13],"2":[14],"and":[15,29,39,67,74,90,95,109,121,138,153,161,219,231],"serotonin":[16],"1A":[17],"receptors.":[18],"The":[19,259],"metabolism":[20,286],"of":[21,37,47,59,65,93,113,144,163,172,207,244,261,266,280],"aripiprazole":[22,38,60,145,230,237,245,267,281],"involves":[23],"both":[24],"cytochrome":[25],"P450":[26],"2D6":[27],"(CYP2D6)":[28],"CYP3A4.":[30],"This":[31],"study":[32],"investigated":[33],"the":[34,40,45,84,91,106,141,164,184,205,208,217,220,262],"pharmacokinetic":[35,242],"variability":[36,80,243,260,279],"active":[41,142,264],"metabolite":[42,68],"dehydroaripiprazole":[43,269],"on":[44,255],"basis":[46],"155":[48],"monitoring":[50],"samples":[51],"from":[52],"psychiatric":[53,249],"patients":[54,155,181,202,250],"treated":[55],"therapeutic":[57],"doses":[58],"(10-30":[61],"mg/day).":[62],"Serum":[63],"concentrations":[64,114],"were":[69,126,166,176,182,224],"determined":[70,284],"by":[71,157,285],"liquid":[72],"chromatographic":[73],"tandem":[75],"mass":[76],"spectrometric":[77],"detection.":[78],"Pharmacokinetic":[79],"was":[81,102,197,211],"expressed":[82],"as":[83],"range":[85,112],"in":[86,151,194,199,216,248],"concentration/dose":[87],"(C/D)":[88],"ratios,":[89],"effect":[92],"sex":[94],"occasionally":[96],"coprescribed":[97,183],"CYP2D6":[98,186],"or":[99,189,257],"CYP3A4":[100,174],"inhibitors/inducers":[101],"studied.":[103],"In":[104,240],"addition,":[105],"dose-concentration":[107,214],"relationship":[108,215],"combined":[110,221],"interquartile":[111,222],"obtained":[115],"low":[117],"dose":[118,123,256],"(10-15":[119],"mg/day)":[120,125],"high":[122],"(20-30":[124],"described.":[127],"Individual":[128],"C/D":[129,149,195],"ratios":[130,150],"ranged":[131],"37-fold":[132],"for":[133,136,140,229,236],"aripiprazole,":[134,276],"78-fold":[135],"dehydroaripiprazole,":[137],"27-fold":[139],"sum":[143,265],"+":[146,238,268],"dehydroaripiprazole.":[147,239,288],"Median":[148],"male":[152],"female":[154],"differed":[156],"less":[158,274],"than":[159,275],"15%,":[160],"none":[162],"differences":[165],"significant":[167],"(P":[168],">":[169],"0.14).":[170],"Cases":[171],"concurrent":[173],"inducers/inhibitors":[175],"not":[177,253],"found,":[178],"but":[179,251],"three":[180,201],"potent":[185],"inhibitors":[187],"paroxetine":[188],"fluoxetine.":[190],"No":[191],"consistent":[192],"difference":[193],"ratio":[196],"observed":[198],"these":[200],"compared":[203],"rest":[206],"patients.":[209],"There":[210],"proportional":[213],"population,":[218],"ranges":[223],"230":[225],"to":[226,233,272,287],"960":[227],"nmol/L":[228,235],"330":[232],"1210":[234],"conclusion,":[241],"extensive":[247],"apparently":[252],"dependent":[254],"sex.":[258],"pharmacologic":[263],"25%":[271],"30%":[273],"suggesting":[277],"that":[278],"partly":[283]},"counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":6},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":6},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":4},{"year":2015,"cited_by_count":6},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":5}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}